Ovarian Hyperstimulation Syndrome Prevention

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-11-17

Study Completion Date

2025-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Ovarian hyperstimulation is a very hazardous complication of ICSI

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Ovarian hyperstimulation could be mild , moderate , severe or marked

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ovarian Hyper Stimulation Syndrome (OHSS)

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

OHSS mild Moderate Severe

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

antagonist

patients with PCOS undergoing ICSI receiving antagonist protocol

Group Type ACTIVE_COMPARATOR

Antagonist protocol for IVF

Intervention Type DRUG

antagonist protocol with triggering by Decapeptyl

Modified agonist with additives

Patients with PCOS undergoing ICSI receiving modified agonist protocol with additives

Group Type ACTIVE_COMPARATOR

Modified Agonist protocol for IVF with additive treatments as HCQ

Intervention Type DRUG

giving additive drugs to agonist protocolas HCQ

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Antagonist protocol for IVF

antagonist protocol with triggering by Decapeptyl

Intervention Type DRUG

Modified Agonist protocol for IVF with additive treatments as HCQ

giving additive drugs to agonist protocolas HCQ

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Antagonist modified agonist with additives

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women with PCOS coming for ICSI

Exclusion Criteria

* Women who donnot have PCOS

Minimum Eligible Age

19 Years

Maximum Eligible Age

42 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mahmoud Alalfy

National Research centre

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mahmoud Alalfy, MD

Role: STUDY_CHAIR

Aljazeera Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Aljazeerah hospital

Giza, , Egypt

Site Status RECRUITING

Algazeerah

Giza, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mahmoud Alalfy, MD

Role: CONTACT

Phone: 01002611058

Email: [email protected]

Ahmed Elgazzar, MD

Role: CONTACT

Phone: 01014005959

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mahmoud Alalfy, MD

Role: primary

Mahmoud Alalfy, master

Role: primary

Ahmed Elgazzar, M.D

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.